- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345
- Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 36,814 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 114 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 212
matching trials from the live ClinicalTrials.gov search.
- Conditions
- RSV Infection
- Interventions
- Clesrovimab
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 8 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- motavizumab (MEDI-524), palivizumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- Up to 24 Months
- Enrollment
- 6,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 120
- States / cities
- Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more
- Conditions
- Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
- Interventions
- Placebo, SeVRSV Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV-F Particle Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Cancer
- Interventions
- palivizumab, ribavirin
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
- Interventions
- Aptitude Medical Systems Respiratory Panel Test
- Diagnostic Test
- Lead sponsor
- Aptitude Medical Systems
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Trussville, Alabama
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 1,177 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV cps2 Vaccine, Placebo Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2013
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Laurel, Maryland
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MEDI8897, Palivizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 1 Year
- Enrollment
- 925 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 30
- States / cities
- Anaheim, California • Long Beach, California • Los Angeles, California + 27 more
- Conditions
- Respiratory Tract Infection
- Interventions
- Formulation A, Formulation B, Formulation C, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
- Conditions
- RSV Infection
- Interventions
- EDP-323, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
- Interventions
- imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
- Device
- Lead sponsor
- The Geneva Foundation
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- MEDI-524 (Numax-TM)
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- COVID-19, SARS-CoV-2 Infection, RSV, Influenza
- Interventions
- Not listed
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 400,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALN-RSV01, Normal Saline
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- AZM Group, Control Group
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 3 Days to 2 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 12 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALN-RSV01
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Covid19
- Interventions
- Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 1, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Two Doses, Intranasal Drops, Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Spray
- Biological
- Lead sponsor
- Meissa Vaccines, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Raleigh, North Carolina
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Placebo, Active
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Day to 60 Months
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • St Louis, Missouri
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Live Music Therapy, Recorded Music Therapy
- Behavioral
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- Up to 2 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- EDP-938, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Augusta, Georgia